Skip to main content
. 2015 Nov 17;5(2):122–131. doi: 10.1016/j.molmet.2015.11.003

Figure 1.

Figure 1

IL-13 decreases human and rat beta-cell death. Human islets, human or rat dispersed islets or sorted human or rat beta-cells were cultured for 48 h with IL-13 (10 ng/ml). A–C: Insulin secretion. A: Human islet insulin secretion: 2.8 mM glucose (open bars), 16.7 mM glucose (closed bars); n = 5. Rat dispersed islet cells (B; n = 5) or sorted beta-cells (C; n = 7) insulin secretion: 2.8 mM glucose (open bars), 16.7 mM glucose (closed bars). D: Rat beta-cell proliferation. BrdU-positive beta-cells in dispersed rat islet cells (normalized to control = 9.98 ± 1.93% BrdU-positive beta-cells); n = 5. E-H Beta-cell death. E: TUNEL-positive beta-cells among dispersed human islet cells (normalized to control = 0.47 ± 0.1% TUNEL-positive beta-cells); n = 5. F: TUNEL-positive sorted human beta-cells (normalized to control = 1.06 ± 0.32% TUNEL-positive beta-cells); n = 4. G: TUNEL-positive beta-cells in dispersed rat islet cells (normalized to control = 0.12 ± 0.03% TUNEL-positive beta-cells); n = 3. H: TUNEL-positive sorted rat beta-cells (normalized to control = 0.06 ± 0.02% TUNEL-positive beta-cells); n = 5. *p < 0.05 vs. control as tested by Student's t-test.